Core Viewpoint - East Asia Pharmaceutical reported significant declines in revenue and net profit for the first three quarters of 2025, indicating financial challenges and operational difficulties [1][2]. Financial Performance - The company's revenue for the first three quarters was 596 million yuan, a year-on-year decrease of 38.08% [1]. - The net profit attributable to shareholders was -72.41 million yuan, a year-on-year decline of 260.31% [1]. - The net profit after deducting non-recurring items was -81.98 million yuan, down 315.27% year-on-year [1]. - Basic earnings per share were -0.63 yuan [1]. Profitability Metrics - The gross profit margin for the first three quarters was 25.96%, down 1.02 percentage points year-on-year [2]. - The net profit margin was -12.15%, a decrease of 16.84 percentage points compared to the same period last year [2]. - In Q3 2025, the gross profit margin was 16.29%, down 13.08 percentage points year-on-year and 9.43 percentage points quarter-on-quarter [2]. - The net profit margin for Q3 was -23.37%, a decline of 27.40 percentage points year-on-year and 13.00 percentage points quarter-on-quarter [2]. Expense Analysis - Total operating expenses for the period were 205 million yuan, an increase of 2.92 million yuan year-on-year [2]. - The expense ratio was 34.41%, up 13.41 percentage points from the previous year [2]. - Sales expenses decreased by 11.36%, management expenses decreased by 3.44%, and R&D expenses decreased by 1.35%, while financial expenses increased by 290.95% [2]. Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 10,700, a decrease of 702 from the end of the previous half-year, representing a decline of 6.17% [3]. - The average market value of shares held per shareholder increased from 186,400 yuan to 208,800 yuan, an increase of 11.99% [3]. Company Overview - Zhejiang East Asia Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang Province, and was established on February 6, 1998, with its listing date on November 25, 2020 [3]. - The company's main business includes the R&D, production, and sales of chemical raw materials and pharmaceutical intermediates [3]. - The revenue composition includes β-lactam antibiotics (44.84%), anticholinergic and synthetic antispasmodic drugs (23.92%), quinolone antibiotics (12.86%), antifungal drugs for skin use (8.87%), and other products [3].

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. has released a rectification report addressing issues related to the use of raised funds, as highlighted by the Zhejiang Securities Regulatory Bureau [1][2][3] Group 1: Rectification Measures - The company plans to adjust the use of raised funds, improve review procedures, and enhance information disclosure to strengthen internal control governance [1][2] - The adjustment includes converting the construction project of the R&D center into a comprehensive administrative building, while maintaining the existing R&D area [2] - The company has organized specialized training for its board members and management to enhance compliance awareness and information disclosure management [2] Group 2: Compliance and Governance - The rectification aims to improve the company's internal control governance, ensuring compliance and promoting sustainable development [3] - The announcement did not indicate any significant impact on the company's daily operations due to these issues [3]

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-052 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于浙江证监局对公司采取责令改正措施决定的 整改报告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江东亚药业股份有限公司（以下简称"公司"）于近日收到中国证券监督 管理委员会浙江监管局（以下简称"浙江证监局"）出具的《关于对浙江东亚药 业股份有限公司采取责令改正措施的决定》（【2025】224 号）（以下简称"决 定书"），要求公司就《决定书》中所提出的问题进行整改。具体内容详见公司 于 2025 年 10 月 23 日在上海证券交易所网站（www.sse.com.cn）披露的《关于 公司收到浙江证监局行政监管措施决定书的公告》（公告编号：2025-048）。 公司收到浙江证监局发来的《决定书》后高度重视并立即向公司全体董事、 监事、高级管理人员及相关部门负责人进行了通报和传达，对《决定书》中涉及 的事项 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-051 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于调整首次公开发行股票募投项目中的 研发中心建设项目用途的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 为提高浙江东亚药业股份有限公司（以下简称"公司"）资产的使用效 率，公司拟将首次公开发行股票募投项目中的研发中心建设项目（以下简称"研 发中心建设项目"）所投建的研发楼永久调整为研发行政综合楼，现有供研发使 用的区域保持不变，同步调整部分建筑面积供其他行政部门综合使用，并将根据 公司研发项目实际情况，适时增加研发实验区域和相关研发设备。 ● 本次调整事项已经公司第四届董事会第十一次会议、第四届监事会第十 次会议分别审议通过，监事会已就此事项发表同意意见。本次调整研发中心建设 项目用途的事项尚需提交公司股东大会审议。 ● 本次对首次公开发行股票募投项目调整的事项能提高公司资产整体使用 效 ...

本次会议由监事会主席徐菁女士主持。会议的召集、召开符合《中华人民共和国 公司法》等法律、法规和《公司章程》的有关规定。出席会议的监事对各项议案进行 了认真审议并做出了如下决议： 二、监事会会议审议情况 （一）审议通过《关于 2025 年第三季度报告的议案》 | 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-049 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 第四届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 浙江东亚药业股份有限公司（以下简称"公司"）第四届监事会第十次会议于 2025 年 10 月 30 日（星期四）在浙江省台州市临海市台州湾经济技术开发区东海第五大道 21 号二楼会议室五以现场表决的方式召开。会议通知已于 2025 年 10 月 24 日以电子邮 件的方式送达各位监事。本次会议应出席监事 3 人，实际出席监事 3 人。 表决情况：同意 3 票，反对 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-050 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 本议案已经公司董事会审计委员会审议通过，并同意提交董事会审议。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《2025 年第三季度报告》。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江东亚药业股份有限公司（以下简称"公司"）第四届董事会第十一次会议于 2025 年 10 月 30 日（星期四）在浙江省台州市临海市台州湾经济技术开发区东海第 五大道 21 号二楼会议室五以现场结合通讯的方式召开。本次会议通知于 2025 年 10 月 24 日以电子邮件的方式发出。本次会议应出席董事 7 人，实际出席董事 7 人。 会议由公司董事长池骋先生主持，监事、高管列席会议。本次会议的召集、召 开符合《中华人民共和国公司法》等法律、法规和《公司章程》的有关规定。 二、董事会会议审议情况 经各 ...

Group 1 - The core point of the article is that Dongya Pharmaceutical (605177.SH) reported a significant decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Group 2 - The total operating revenue for the first three quarters of 2025 was 596 million yuan, representing a year-on-year decrease of 38.08% [1] - The net profit attributable to shareholders of the parent company was -72.41 million yuan, compared to a net profit of 45.17 million yuan in the same period last year [1] - The basic earnings per share were -0.63 yuan [1]

浙江东亚药业股份有限公司 2025 年第三季度报告 证券代码：605177 证券简称：东亚药业 债券代码：111015 债券简称：东亚转债 浙江东亚药业股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上 | | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 年同期增减变 | 年初至报告期末 | 比上年同期增减 | | | | 动幅度(%) | | 变动幅度(%) | | 营业收入 | 180,480,644.42 | - ...

Policy Developments - Liaoning Province will implement direct payment of maternity allowances to employees starting November 1, 2025, enhancing convenience and satisfaction for the public [1] Drug and Device Approvals - Hengrui Medicine's subsidiary received clinical trial approval for injection of Rukang Qutuzumab, aimed at treating advanced non-small cell lung cancer [2] - Jibeier received approval for the market application of the chemical raw material drug, Gatifloxacin, which is expected to support its production needs [3] Financial Reports - Ping An Good Doctor reported a 13.6% increase in revenue to 3.725 billion, with a net profit of 216 million, up 45.7% year-on-year [4] - Te Yi Pharmaceutical achieved a 985% increase in net profit, reporting 65.22 million in the first three quarters, with significant growth in traditional Chinese medicine sales [5] - Lijun Pharmaceutical reported a revenue of 9.116 billion, a slight increase of 0.38%, with a net profit of 1.754 billion, up 4.86% [6] Capital Market - In Shanghai's Baoshan District, 17 key biopharmaceutical projects were signed, with total investments exceeding 2 billion, aimed at enhancing the local biopharmaceutical industry [7][8] Industry Developments - Baiyang Pharmaceutical signed a cooperation agreement with Peking University International Hospital to establish a radiosurgery treatment center, enhancing access to high-quality medical resources [10] - Qiang Brain Technology established a new company in Chengdu focusing on AI-related businesses, including medical devices and internet data services [11] Regulatory Actions - The Shanghai Stock Exchange issued a regulatory warning to Zhejiang Dongya Pharmaceutical for discrepancies in the use of raised funds, highlighting the responsibility of the company's former board secretary [12]

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. is facing regulatory scrutiny due to discrepancies in the use of raised funds compared to what was disclosed in its IPO prospectus, leading to a warning for its former board secretary and ongoing financial challenges for the company [1][2][3]. Group 1: Regulatory Issues - Zhejiang Securities Regulatory Bureau found that Dongya Pharmaceutical's actual use of raised funds did not align with the disclosures made in its IPO prospectus, and the company failed to follow internal review procedures for these changes [2]. - The company has been ordered to rectify these issues, and the violations will be recorded in the securities market's integrity archives [2][3]. Group 2: Financial Performance - Dongya Pharmaceutical's revenue for 2022, 2023, 2024, and the first half of 2025 were reported at 1.18 billion, 1.36 billion, 1.20 billion, and 416 million respectively, with year-on-year growth rates of 65.62%, 15.00%, -11.66%, and -35.85% [4]. - The net profit attributable to shareholders for the same periods was 104 million, 121 million, -101 million, and -30.23 million, with year-on-year growth rates of 52.46%, 16.11%, -183.02%, and -193.09% [4]. - The company's debt-to-asset ratio has increased from 25.56% in 2022 to 47.70% in the first half of 2025, indicating rising financial leverage [4]. Group 3: Business Challenges - Dongya Pharmaceutical's core antibacterial drug business is under significant pressure due to the government's "antibiotic restriction orders," which have limited the market space for antibacterial drugs [5][6]. - The company has attempted to implement a "raw material drug formulation integration" strategy, but progress has been slow, with only one of over ten submitted formulations receiving approval [7]. - The existing product structure remains heavily reliant on antibacterial drugs, exposing the company to substantial market and policy risks [7].